Haloperidol의 약물속도론적 연구 (III) -정신분열증 환자에 있어서 Haloperidol의 일회 주사 및 경구투여시의 Pharmacokinetics-

• 영문명: Pharmacokinetics of Haloperidol (III) The Pharmacokinetics of Haloperidol after single oral and intravenous doses in schizophrenic patients
• 발행기관: 대한약학회
• 저자명: 박경호(Kyoung Ho Park) 이민화(Min Hwa Lee) 이명걸(Myung Gull Lee) 권준수(Jun Soo Kwon) 박원명(Won Myung Park) 박진생(Jin Seng Park)
• 간행물 정보: 『약학회지』제34권 제6호 (1990년), 375~383쪽, 전체 9쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 1990.12.28

영문 초록

The pharmacokinetics of haloperidol were determined after single oral and intravenous doses in 13 male schizophrenic patients. Plasma concentrations of haloperidol(HP) and reduced haloperidol were measured by high performance liquid chromatography. Plasma concentration data obtained were analyzed by obth model dependent (one-or two exponential decay models using nonlinear regression) and model independent (AUC and first moment curve) approaches. The two methods were found to be in close results. After intravenous injections of HP in 8 patients (10 mg/man), the mean central and peripheral volume of distribution were 2.85+/-1.7O and 8.09+/-2.10 l/kg, respectively, and mean steady, state volume of distribution was 11.87+/-3.21 l/kg. Mean clearance, MRT and elimination half life were 12.39+/-3.25 ml/min/kg, 925.1O+/-166.79 min and 676.35+/-126.45 min,respectively. After oral administrations of HP in 5 patients, mean peak time and peak concentration were 2l7.63+/-61.60min and 9.77+/-2.92ng/ml, respectively. Mean MRT and elimination half life were 1112.23+/-131.73 min and 724.02+/-120.03 min, respectively, and these parameters were not significantly different from those of intravenous injection of HP. Absolute bioavailability of HP oral product was found to be about 44%. The profiles of plasma RH concentration-time curves after oral or intravenous doses of HP were similar. Also it was found that the elimination rate of RH was slower than that of HP by comparing the slopes of plasma concentration-time curves of HP and RH.

키워드

Haloperidol reduced haloperidol pharmacokinetics schizophrenic patient plasma concentration